Neuroblastoma Precision Trial



Status:Recruiting
Conditions:Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:1 - 30
Updated:8/22/2018
Start Date:August 2016
End Date:December 2019
Contact:Shahab Asgharzadeh, MD
Email:sasgharzadeh@chla.usc.edu
Phone:323-361-8643

Use our guide to learn which trials are right for you!

N2015-01: Neuroblastoma Precision Trial

This proposal sets forth the platform for a Precision Medicine clinical trial through the New
Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's
established multi-institutional infrastructure and Translational Genomics Research Institute
GEM sequencing platform for acquisition and gene panel sequencing of relapsed biological
specimens in relapsed/refractory neuroblastoma (rNB) including those obtained from the bone,
bone marrow or soft tissue. Our primary aim is to identify subgroups of rNB patients who have
potentially targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or
immunologic (tumor-associated macrophage infiltration and/or programmed death ligand [PD-L1]
expression) biomarkers in rNB. Additional potential novel biomarkers will also be evaluated
and reported in this cohort of patients.

Neuroblastoma (NB) is the most common extracranial solid tumor of childhood. High-risk NB is
highly lethal and responsible for over 15% of childhood cancer related deaths. The majority
of patients with metastatic NB respond to upfront cytotoxic chemotherapy, yet patients who
die of recurrent disease do so from tumor acquired resistance to treatment. Thus,
understanding the repertoire of tumor specific genomic alterations leading to tumor
progression and therapy resistance is critical to devising novel targeted therapy options for
patients with recurrent or refractory (r)NB. Limited data exists regarding the genetic and
immunologic predictive biomarkers in rNB, which can be used to direct targeted therapies.
Another barrier to clinical implementation of genetic testing of tumor samples from children
with rNB is obtaining sufficient number of tumor cells from bone marrow (BM) specimens, the
most easily accessible and common site of relapse. This proposal sets forth the platform for
a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy
(NANT) consortium. The plan is to utilize NANT's established multi-institutional
infrastructure and Translational Genomics Research Institute (TGen) GEMTM sequencing platform
for acquisition and gene panel sequencing of relapsed biological specimens in rNB including
those obtained from the bone, bone marrow or soft tissue. Our primary aim is to identify
subgroups of rNB patients who have potentially targetable genetic (ALK, MAPK pathway,
Metabolic-related genes) and/or immunologic (tumor-associated macrophage infiltration and/or
PD-L1 expression) biomarkers in rNB. Additional potential novel biomarkers will also be
evaluated and reported in this cohort of patients. This aim has immediate impact on the lives
of children with rNB as it provides a clinical report to patients and their physicians
detailing observed mutations and rNB subgroups and information on clinical trials that best
match them. Our second aim will assess a novel method for enriching tumor cells from bone
marrow aspirates containing less than 30% tumor involvement so that next generation
sequencing can be performed. Our bone marrow (BM) enrichment protocol has both methodological
and patient significance; 1) BM enrichment will allow a much larger group of rNB patients
access to future personalized medicine trials and 2) Successful confirmation that BM
enrichment can produce quality DNA for genetic analysis serves as proof of principal that
this method can be used for genetic testing of BM with evidence of metastasis in other adult
or pediatric solid tumors. In summary, our proposal will define the genetic and immunologic
landscape of rNB and contribute to our understanding and ability to therapeutically target
the dynamic alterations in tumor biology of children with rNB.

Inclusion Criteria:

- Patients must be ≥ 1 year and ≤ 30 years of age at study registration

- Patients must have had a diagnosis of neuroblastoma either by histological
verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow
with increased urinary catecholamines.

- Patients must have a history of high-risk neuroblastoma according to

- COG risk classification at the time of study registration. Patients must have at least
one of the following: Recurrent/progressive disease, Refractory disease, Persistent
disease

- Patient must be willing to undergo a clinically indicated biopsy and meet at least one
of the following requirements: Bone biopsy, Soft tissue biopsy, Bone marrow biopsy and
aspirate

- Patients must not be receiving any other anti-cancer agents or radiotherapy during the
interval

Exclusion Criteria:

- Patients with disease of any major organ system that would compromise their ability to
withstand biopsy procedures of soft tissue, bone and/or bone marrow.

- Patients who enroll and successfully receive a NANT Precision Report may not re-enroll
at a future time.

- Patient declines participation in NANT 2004-05, the NANT Biology Study.
We found this trial at
11
sites
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Phone: 513-636-9866
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Ann Arbor, MI 48109Bus: -
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Boston, Massachusetts 02115
Phone: 617-632-3725
?
mi
from
Boston, MA
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Phone: 323-361-5687
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1600 Divisadero Street
San Francisco, California 94115
888.689.8273
Phone: 415-476-3831
UCSF Helen Diller Family Comprehensive Cancer Center UCSF’s long tradition of excellence in cancer research...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
1405 Clifton Road NE
Atlanta, Georgia 30322
404-785-6000
Phone: 404-785-0853
Children's Healthcare of Atlanta Whether treating a toddler in an emergency or supporting a teen...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Aurora, Colorado 80045
Phone: 720-777-8856
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
2515 N Clark St
Chicago, Illinois 60614
(312) 227-6060
Phone: 773-843-3943
Children's Memorial Hospital, Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Fort Worth, Texas 76104
Phone: 682-885-4007
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Seattle, Washington 98105
Phone: 206-987-5783
?
mi
from
Seattle, WA
Click here to add this to my saved trials